Eflapegrastim
Eflapegrastim is a composite protein consisting of a genetically modified granulocyte-colony stimulating factor (GCSF) molecule linked via a chemical bond to an IgG4 Fc fragment (LAPS-carrier). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia.
For research use only. We do not sell to patients.
- CAS No.: 1384099-30-2
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CSF3R
In Vitro
Eflapegrastim has an IgG4 Fc fragment and short polyethylene glycol linker[1].
Eflapegrastim (5.5-88 mM; 4 min) binds to FcRn but not Fcγ receptors or C1q[1].
Eflapegrastim (0.000036-0.709 nmol/L; 54 h) induces bone marrow cell proliferation[1].
Eflapegrastim (10 μM; 1 h) binds FcRn and undergoes FcRn-mediated transcytosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6NCrl mice (4-6 weeks old)[1]
-
Dosage:(1) 9, 26, 53, and 88 µg/kg; (2) 62 µg/kg
-
Administration:Subcutaneous injection; single dose
-
Result:Reduced chemotherapy-induced neutropenia.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1384099-30-2
-
SMILES
[Eflapegrastim]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Eflapegrastim Related Classifications
HY-P99913 Related Classifications
Powered by Bioz